Two Different Pathways
The pituitary gland's growth hormone output is regulated by two primary inputs: GHRH (Growth Hormone-Releasing Hormone) signals the pituitary to release GH; ghrelin (and its receptor GHSR) amplifies the GH pulse. CJC-1295 mimics GHRH. Ipamorelin mimics ghrelin. Using them together simultaneously activates both stimulatory pathways — producing a larger GH release than either compound alone.
CJC-1295 with DAC: The Sustained Release Element
CJC-1295 with DAC has a half-life of approximately 7–8 days, meaning it provides a sustained background stimulation of the pituitary's GHRH receptors. Human trials published in the Journal of Clinical Endocrinology & Metabolism showed a 2–10 fold increase in GH levels that persisted for over 6 days after a single injection.
Ipamorelin: The Clean Pulse
Ipamorelin adds the ghrelin receptor stimulation component — triggering a pulse of GH release. What makes it particularly suitable for stacking is its selectivity: unlike GHRP-6 (another ghrelin mimetic), Ipamorelin does not significantly raise cortisol or prolactin, which can blunt the anabolic effects of GH release.
Enjoying this? Get weekly peptide research in your inbox →